Should adjuvant nivolumab be used in surgically resected Merkel cell carcinoma patients?
- PMID: 37451294
- DOI: 10.1016/S0140-6736(23)01041-3
Should adjuvant nivolumab be used in surgically resected Merkel cell carcinoma patients?
Conflict of interest statement
PS and AB report consultancy fees from Merck Serono broadly related to treatments for Merkel cell carcinoma but unrelated to the topic of this Comment. PS reports consultancy fees from MSD and BMS outside of the topic of this Comment.
Comment on
-
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.Lancet. 2023 Sep 2;402(10404):798-808. doi: 10.1016/S0140-6736(23)00769-9. Epub 2023 Jul 11. Lancet. 2023. PMID: 37451295 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
